<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01945840</url>
  </required_header>
  <id_info>
    <org_study_id>MR/K02115X/1</org_study_id>
    <nct_id>NCT01945840</nct_id>
  </id_info>
  <brief_title>Gut Hormones and Roux en Y Gastric Bypass</brief_title>
  <official_title>Do Gut Hormones Mediate the Beneficial Effects of Roux-en-Y Bypass?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether the changes in gut hormones seen following
      Roux en Y Gastric Bypass surgery are responsible for some of the beneficial effects seen
      post-operatively.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>Baseline - 4 weeks</time_frame>
    <description>Weight loss as measured at baseline compared to 4 weeks after infusion or diet</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycaemia</measure>
    <time_frame>Baseline - 4 weeks</time_frame>
    <description>As assessed by change in fructosamine and HbA1c levels</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Roux en Y Gastric Bypass</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be those already scheduled to undergo Roux en Y Gastric Bypass Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gut hormone infusion (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of three gut hormones - GLP-1, PYY and oxyntomodulin subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gut hormone infusion (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of three gut hormones - GLP-1, PYY and oxyntomodulin subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline infusion given subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Very low calorie diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be asked to follow a very low calorie diet for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux en Y Gastric Bypass Surgery</intervention_name>
    <arm_group_label>Roux en Y Gastric Bypass</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gut hormone infusion (high dose)</intervention_name>
    <arm_group_label>Gut hormone infusion (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gut hormone infusion (low dose)</intervention_name>
    <arm_group_label>Gut hormone infusion (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <arm_group_label>Placebo infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Very low calorie diet</intervention_name>
    <arm_group_label>Very low calorie diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index ≤50 kg/m2.

          -  Eligible for bariatric surgery under the NHS.

          -  Diagnosed with impaired glucose regulation or type 2 diabetes, according to WHO 2011
             criteria. For the dose finding study, non-diabetics can also be recruited.

          -  Those with diabetes should be stable and well controlled with either diet or one oral
             hypoglycaemic agent.

          -  HbA1c ≤8.0% or 64 mmol/mol.

        Exclusion Criteria:

          -  History of any medical, psychological or other condition, or use of any medications,
             including over-the-counter products, which, in the opinion of the investigators, would
             either interfere with the study or potentially cause harm to the volunteer.

          -  Without access at home to a telephone or other factor likely to interfere with ability
             to participate reliably in the study.

          -  Pregnancy or breastfeeding.

          -  Smokers.

          -  Unable to maintain adequate contraception for the duration of the study and for one
             month afterwards.

          -  History of hypersensitivity to any of the components of the subcutaneous infusions.

          -  Donated blood during the preceding 3 months or intention to do so before the end of
             the study.

          -  Insulin treatment.

          -  Uncontrolled hypertension.

          -  Any other co-morbidity that would compromise the validity of the study or the safety
             of the participant such as heart failure, clinically apparent cardiovascular disease.

          -  Unable to give informed consent.

          -  Previous bariatric surgery.

          -  Unable to undergo fMRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen R Bloom, FRS FRCP MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tricia Tan, MBChB MRCP</last_name>
    <email>t.tan@imperial.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>NIHR/Wellcome Trust Imperial CRF, Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stephen R Bloom, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2013</study_first_submitted>
  <study_first_submitted_qc>September 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2013</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

